Elyns Joural of Surgery

Editor in Chief

Dr. DiGiacomo earned his Bachelor’s of Arts from the University of Pennsylvania and his Medical Degree from the Temple University School of Medicine. After his surgical residency at St. Francis Medical Center in Trenton, New Jersey, Dr. DiGiacomo completed a two year fellowship in Trauma and Surgical Critical Care at the University of Pennsylvania. Dr. DiGiacomo…

Name : Jody C. DiGiacomo
University : Nassau University Medical Center

Indexing and Listing

          

Recent Articles

  • Pediatric Abdominal Trauma in Sub Saharan Africa

    Trauma is recognized as a leading cause of morbidity and mortality in children worldwide. Trauma to the abdomen in children can occur isolated, but frequently, in association with other regions of the body. It is now being increasingly recognized as a significant health problem in African children. Whereas childhood infectious disease control had taken…

    View more

PubMed Indexed Articles

  • Homeodomain Transcription Factor Msx-2 Regulates Uterine Progenitor Cell Response to Diethylstilbestrol

    The fate of mouse uterine epithelial progenitor cells is determined between postnatal days 5 to 7. Around this critical time window, exposure to an endocrine disruptor, diethylstilbestrol (DES), can profoundly alter uterine cytodifferentiation. We have shown previously that a homeo domain transcription factor MSX-2 plays an important role in DES-responsiveness…

    View more
  • Brain Uptake of Neurotherapeutics after Intranasal Delivery in Mice

    There is a growing global prevalence of neurodegenerative diseases such as Alzheimer’s disease and dementia. Current treatment for neurodegenerative diseases is limited due to the blood brain barrier’s ability to restrict the entry of therapeutics to the brain. In that context, direct delivery of drugs from nose to brain has gained emerging interest…

    View more
  • Current Studies of Immunotherapy on Glioblastoma

    Glioblastoma is a form of brain tumor with a very high morbidity and mortality. Despite decades of research, the best treatments currently in clinical practice only extend survival by a number of months. A promising alternative to conventional treatment for glioblastomas is immunotherapy. Although proposed over a century ago, the field of cancer immunotherapy…

    View more

Testimonial